HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN Article
Full Text via DOI: 10.1016/S0735-1097(16)30806-3
Web of Science: 000375188701649
Industry Collaboration